Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Allogene Therapeutics, Inc.ALLO · Entity 5243 | Director | June 18, 2026 | June 23, 2026 |
| BORGWARNER INCBWA · Entity 3425 | Director | April 29, 2020 | May 01, 2020 |
| BRISTOL MYERS SQUIBB COBMY · Entity 1662 | Director | February 01, 2021 | February 04, 2021 |
| Denali Therapeutics Inc.DNLI · Entity 1735 | Director | January 02, 2025 | January 03, 2025 |
| REVVITY, INC.PKI · Entity 3382 | Director | February 09, 2017 | February 10, 2017 |
| Syros Pharmaceuticals, Inc.SYRS · Entity 85437 | Director | June 11, 2019 | June 12, 2019 |
| Vir Biotechnology, Inc.VIR · Entity 4522 | Director | May 01, 2026 | May 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Allogene Therapeutics, Inc.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 95,400 |
Reported balance
After 2026-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 95,400 · Balance 95,400 F1: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date.
BORGWARNER INC
Report date April 29, 2020 · Filed May 01, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,823.19 |
Reported balance
After 2020-04-29 transaction · row 1
1 source rowRow 1 · 2020-04-29 · Grant · Acquired 4,382 · Balance 19,823.19 F1: The shares will vest 100% on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares will vest 100% on the first anniversary of the grant date.
BRISTOL MYERS SQUIBB CO
Report date February 01, 2021 · Filed February 04, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Share UnitsSEC Table II · derivative / convertible security | Direct | 75,689.427 |
Reported balance
After 2021-02-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-01 · Grant · Acquired 3,054.171 · Balance 75,689.427 F1: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.
F2: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Denali Therapeutics Inc.
Report date January 02, 2025 · Filed January 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 107,976 |
Reported balance
After 2025-01-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-01-02 · Sale · Disposed 3,080 · Balance 107,976 F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted March 21, 2024. F2: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $20.75 to $21.06 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3: Includes 5,967 unvested RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted March 21, 2024.
F2: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $20.75 to $21.06 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3: Includes 5,967 unvested RSUs.
REVVITY, INC.
Report date February 09, 2017 · Filed February 10, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 29,970 |
Ending reported balance
After 2017-02-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-02-09 · Exercise / conversion · Acquired 8,308 · Balance 38,278 Row 2 · 2017-02-09 · Sale · Disposed 8,308 · Balance 29,970 |
| NQ Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.36 · Expires 2017-05-11 | Direct | 0 |
Reported balance
After 2017-02-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-02-09 · Exercise / conversion · Disposed 8,308 · Balance 0 F1: This option became exercisable in three equal annual installments beginning on May 11, 2011, which was the first anniversary of the date on which the option was granted, and had a 7 year exercise term. |
Filing footnotes · ownership attribution and instrument terms
F1: This option became exercisable in three equal annual installments beginning on May 11, 2011, which was the first anniversary of the date on which the option was granted, and had a 7 year exercise term.
Syros Pharmaceuticals, Inc.
Report date June 11, 2019 · Filed June 12, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.60 · Expires 2029-06-10 | Direct | 11,000 |
Reported balance
After 2019-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-11 · Grant · Acquired 11,000 · Balance 11,000 F1: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date.
Vir Biotechnology, Inc.
Report date May 01, 2026 · Filed May 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,078,391 |
Reported balance
After 2026-05-01 transaction · row 1
1 source rowRow 1 · 2026-05-01 · Sale · Disposed 22,000 · Balance 1,078,391 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.94 to $10.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.94 to $10.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Akouos, Inc.
Report date December 01, 2022 · Filed December 02, 2022
Section 16 reporting ended · disclosed 2022-12-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.38 · Expires 2030-05-11 | Direct | 0 |
Reported balance
After 2022-12-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-12-01 · Disposition to issuer · Disposed 26,930 · Balance 0 F1: At the effective time of the merger (the "Effective Time"), pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Kearny Acquisition Corporation ("Merger Sub"), dated as of October 17, 2022, each outstanding option to purchase shares of common stock, par value $0.0001 per share, of the Issuer ("Shares") having an exercise price less than $12.50 per Share, whether or not vested, was cancelled and converted into the right to receive (x) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (A) the total number of Shares subject to such option immediately prior to the Effective Time multiplied by [Continued on Note 2] F2: [Continuation of Note 1] (B) the excess, if any, of $12.50 per Share over the applicable exercise price per Share under such option and (y) one non-tradable contingent value right ("CVR") for each Share subject to such option immediately prior to the Effective Time (without regard to vesting), which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Parent, Merger Sub, Computershare Inc. and Computershare Trust Company, N.A. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.38 · Expires 2030-05-11 | Direct | 0 |
Reported balance
After 2022-12-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-12-01 · Disposition to issuer · Disposed 12,100 · Balance 0 F1: At the effective time of the merger (the "Effective Time"), pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Kearny Acquisition Corporation ("Merger Sub"), dated as of October 17, 2022, each outstanding option to purchase shares of common stock, par value $0.0001 per share, of the Issuer ("Shares") having an exercise price less than $12.50 per Share, whether or not vested, was cancelled and converted into the right to receive (x) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (A) the total number of Shares subject to such option immediately prior to the Effective Time multiplied by [Continued on Note 2] F2: [Continuation of Note 1] (B) the excess, if any, of $12.50 per Share over the applicable exercise price per Share under such option and (y) one non-tradable contingent value right ("CVR") for each Share subject to such option immediately prior to the Effective Time (without regard to vesting), which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Parent, Merger Sub, Computershare Inc. and Computershare Trust Company, N.A. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.21 · Expires 2032-06-22 | Direct | 0 |
Reported balance
After 2022-12-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-12-01 · Disposition to issuer · Disposed 16,000 · Balance 0 F1: At the effective time of the merger (the "Effective Time"), pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Kearny Acquisition Corporation ("Merger Sub"), dated as of October 17, 2022, each outstanding option to purchase shares of common stock, par value $0.0001 per share, of the Issuer ("Shares") having an exercise price less than $12.50 per Share, whether or not vested, was cancelled and converted into the right to receive (x) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (A) the total number of Shares subject to such option immediately prior to the Effective Time multiplied by [Continued on Note 2] F2: [Continuation of Note 1] (B) the excess, if any, of $12.50 per Share over the applicable exercise price per Share under such option and (y) one non-tradable contingent value right ("CVR") for each Share subject to such option immediately prior to the Effective Time (without regard to vesting), which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Parent, Merger Sub, Computershare Inc. and Computershare Trust Company, N.A. |
Filing footnotes · ownership attribution and instrument terms
F1: At the effective time of the merger (the "Effective Time"), pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Kearny Acquisition Corporation ("Merger Sub"), dated as of October 17, 2022, each outstanding option to purchase shares of common stock, par value $0.0001 per share, of the Issuer ("Shares") having an exercise price less than $12.50 per Share, whether or not vested, was cancelled and converted into the right to receive (x) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (A) the total number of Shares subject to such option immediately prior to the Effective Time multiplied by [Continued on Note 2]
F2: [Continuation of Note 1] (B) the excess, if any, of $12.50 per Share over the applicable exercise price per Share under such option and (y) one non-tradable contingent value right ("CVR") for each Share subject to such option immediately prior to the Effective Time (without regard to vesting), which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Parent, Merger Sub, Computershare Inc. and Computershare Trust Company, N.A.
VERTEX PHARMACEUTICALS INC / MA
Report date May 11, 2005 · Filed May 12, 2005
Section 16 reporting ended · disclosed 2005-05-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 77,233 |
Ending reported balance
After 2005-05-11 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2005-05-11 · Exercise / conversion · Acquired 7,000 · Balance 115,108 Row 2 · 2005-05-11 · Sale · Disposed 7,000 · Balance 108,108 F1: Transaction made pursuant to Dr. Sato's company approved trading plan established under Rule 10b5-1. Row 3 · 2005-05-11 · Disposition to issuer · Disposed 2,000 · Balance 106,108 F2: Restricted Shares repurchased by the Company pursuant to a Severance Agreement and Release dated February 7, 2005. Row 4 · 2005-05-11 · Disposition to issuer · Disposed 28,875 · Balance 77,233 F2: Restricted Shares repurchased by the Company pursuant to a Severance Agreement and Release dated February 7, 2005. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $9.50 · Expires 2005-12-13 | Direct | 910,655 |
Reported balance
After 2005-05-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2005-05-11 · Exercise / conversion · Disposed 7,000 · Balance 910,655 F3: Right to buy under 1994 Stock and Option Plan, vesting quarterly over 5 years from 12/14/1995. F4: Reflects option to purchase 61,164 shares of common stock cancelled by the Company pursuant to a Severance Agreement and Release dated February 7, 2005. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 8,084 |
Reported balance
Holding disclosure · report date 2005-05-11 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 8,084 |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Dr. Sato's company approved trading plan established under Rule 10b5-1.
F2: Restricted Shares repurchased by the Company pursuant to a Severance Agreement and Release dated February 7, 2005.
F3: Right to buy under 1994 Stock and Option Plan, vesting quarterly over 5 years from 12/14/1995.
F4: Reflects option to purchase 61,164 shares of common stock cancelled by the Company pursuant to a Severance Agreement and Release dated February 7, 2005.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 14, 2018 Filed Jun 15, 2018 20:29 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $12.95 | $0.00 |
DisclosureSEC source: 0001179110-18-008622 · edgar.xml · derivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2028-06-13 F1 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 22:27 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 27,830 | $0.00 Strike: $18.92 | $0.00 |
DisclosureSEC source: 0001209191-18-038152 · doc4.xml · derivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,830 Underlying: Common Stock · 27,830 shares Expires 2028-06-12 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of the one year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, in each case, provided that the Reporting Person continues to serve as a non-employee director through the applicable vesting date. Read SEC document |
| April 25, 2018 Filed Apr 27, 2018 20:01 UTC | BORGWARNER INC BWA · Entity 3425 | GrantCommon Stock | 2,457 | $52.91 | $129,999.87 |
DisclosureSEC source: 0001225208-18-008166 · doc4.xml · nonDerivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,377.98 F1 · shares: The shares will vest 100% on the first anniversary of the grant date. Read SEC document |
| April 25, 2018 Filed May 1, 2018 18:32 UTC Amendment | BORGWARNER INC BWA · Entity 3425 | GrantCommon Stock | 2,457 | $52.91 | $129,999.87 |
DisclosureSEC source: 0001225208-18-008303 · doc4a.xml · nonDerivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,377.98 F1 · security: The shares will vest 100% on the first anniversary of the grant date. F2 · shares: This amendment to the original Form 4 does not amend any item originally reported in Table 1 and the first line item of Table 1 is restated in this amendment for the sole purpose of gaining access to the electronic filing system; footnotes relating to such first line item are included for completeness and have not been amended. This amendment is made by the Reporting Person solely to include the power of attorney attached hereto as Exhibit 24. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:21 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 2,945.86 | $62.80 | $185,000.01 |
DisclosureSEC source: 0000014272-18-000050 · wf-form4_151787290328860.xml · derivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,784.421 Underlying: Common Stock, $0.10 par value · 2,945.86 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 12, 2017 Filed Dec 12, 2017 22:42 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionSeries A-1 Preferred Stock · Derivative | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-065248 · doc4.xml · derivative · entry 2 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 62,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.exercise_date: The Series A-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.expiration_date: The Series A-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. Read SEC document |
| December 12, 2017 Filed Dec 12, 2017 22:42 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionCommon Stock | 62,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-065248 · doc4.xml · nonDerivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. Read SEC document |
| December 07, 2017 Filed Dec 8, 2017 22:58 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 47,165 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-17-064809 · doc4.xml · derivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,165 Underlying: Common Stock · 47,165 shares Expires 2027-12-06 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on December 7, 2018 and an additional 1/48 of the shares vest monthly thereafter. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 20:03 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $14.26 | $0.00 |
DisclosureSEC source: 0001179110-17-008896 · edgar.xml · derivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2027-06-07 F1 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the award, with the remainder vesting in equal monthly installments until the first anniversary of the date of the award, subject to the reporting person's continued service as a director through each applicable vesting date. Read SEC document |
| June 08, 2017 Filed Sep 22, 2017 21:20 UTC Amendment | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $14.62 | $0.00 |
DisclosureSEC source: 0001179110-17-012630 · edgar.xml · derivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2027-06-07 F2 · derivative.exercise_price: This amendment to the Statement of Changes in Beneficial Ownership of Securities on Form 4 filed with the Securities and Exchange Commission on June 12, 2017 is being filed to correct a typographical error in the exercise price of the option to purchase Common Stock held by the reporting person. F1 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the award, with the remainder vesting in equal monthly installments until the first anniversary of the date of the award, subject to the reporting person's continued service as a director through each applicable vesting date. Read SEC document |
| April 26, 2017 Filed Apr 28, 2017 12:04 UTC | BORGWARNER INC BWA · Entity 3425 | GrantCommon Stock | 2,991 | $41.13 | $123,004.88 |
DisclosureSEC source: 0001225208-17-008568 · doc4.xml · nonDerivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,920.98 F1 · shares: The shares will vest 100% on the first anniversary of the grant date. Read SEC document |
| February 09, 2017 Filed Feb 10, 2017 21:29 UTC | REVVITY, INC. PKI · Entity 3382 | Exercise / conversionNQ Stock Option (right to buy) · Derivative | 8,308 | $0.00 Strike: $23.36 | $0.00 |
DisclosureSEC source: 0000899243-17-003481 · doc4.xml · derivative · entry 3 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,308 shares Expires 2017-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option became exercisable in three equal annual installments beginning on May 11, 2011, which was the first anniversary of the date on which the option was granted, and had a 7 year exercise term. Read SEC document |
| February 09, 2017 Filed Feb 10, 2017 21:29 UTC | REVVITY, INC. PKI · Entity 3382 | SaleCommon Stock | 8,308 | $54.01 | $448,715.08 |
DisclosureSEC source: 0000899243-17-003481 · doc4.xml · nonDerivative · entry 2 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,970 Read SEC document |
| February 09, 2017 Filed Feb 10, 2017 21:29 UTC | REVVITY, INC. PKI · Entity 3382 | Exercise / conversionCommon Stock | 8,308 | $23.36 | $194,074.88 |
DisclosureSEC source: 0000899243-17-003481 · doc4.xml · nonDerivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,278 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 22:20 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 3,448.975 | $49.29 | $169,999.98 |
DisclosureSEC source: 0000014272-17-000037 · wf-form4_148616039502288.xml · derivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,355.865 Underlying: Common Stock, $0.10 par value · 3,448.975 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 10:57 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantStock Option (right to buy) · Derivative | 22,000 | $0.00 Strike: $12.59 | $0.00 |
DisclosureSEC source: 0001104659-16-145306 · a4.xml · derivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2026-09-14 F1 · derivative.exercise_date: The option becomes exercisable as to 16.66% of the shares underlying the award on the six month anniversary of the award, with the remainder vesting in equal monthly installments of 2.77% of the shares underlying the award until the third anniversary of the date of the award, subject to Dr. Sato's continued service as a director through each applicable vesting date. Read SEC document |
| February 01, 2016 Filed Feb 3, 2016 21:59 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 2,795.133 | $60.82 | $169,999.99 |
DisclosureSEC source: 0000014272-16-000275 · wf-form4_145453675640941.xml · derivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,596.171 Underlying: Common Stock, $0.10 par value · 2,795.133 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| February 01, 2015 Filed Feb 3, 2015 23:17 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 2,654.72 | $60.27 | $159,999.97 |
DisclosureSEC source: 0000014272-15-000040 · wf-form4_142300542977041.xml · derivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,705.16 Underlying: Common Stock, $0.10 par value · 2,654.72 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| February 01, 2014 Filed Feb 4, 2014 21:53 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 3,192 | $50.12 | $159,983.04 |
DisclosureSEC source: 0000014272-14-000034 · wf-form4_139155082388889.xml · derivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,603.14 Underlying: Common Stock, $0.10 par value · 3,192 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| February 01, 2013 Filed Feb 5, 2013 21:18 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 4,364 | $36.66 | $159,984.24 |
DisclosureSEC source: 0001225208-13-002983 · doc4.xml · derivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,500.44 Underlying: Common Stock, $0.10 par value · 4,364 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| February 01, 2012 Filed Feb 3, 2012 21:33 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 4,313 | $32.46 | $139,999.98 |
DisclosureSEC source: 0001225208-12-003081 · doc4.xml · derivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,827.7 Underlying: Common Stock, $0.10 par value · 4,313 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| February 01, 2011 Filed Feb 3, 2011 20:38 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 4,935 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-004711 · doc4.xml · derivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,290.56 Underlying: Common Stock, $0.10 par value · 4,935 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted on a 1 for 1 basis into a share of common stock. Directors will receive shares upon settlement. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted on a 1 for 1 basis into a share of common stock. Directors will receive shares upon settlement. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted on a 1 for 1 basis into a share of common stock. Directors will receive shares upon settlement. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| February 01, 2010 Filed Feb 2, 2010 18:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 4,490 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-10-003024 · doc4.xml · derivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,053.96 Underlying: Common Stock, $0.10 par value · 4,490 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted on a 1 for 1 basis into a share of common stock. Directors will receive shares upon settlement. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted on a 1 for 1 basis into a share of common stock. Directors will receive shares upon settlement. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted on a 1 for 1 basis into a share of common stock. Directors will receive shares upon settlement. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| February 02, 2009 Filed Feb 26, 2009 16:55 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 5,093 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-09-004962 · doc4.xml · derivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,849.39 Underlying: Common Stock, $0.10 par value · 5,093 shares Expires not disclosed F1 · derivative.exercise_price: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. F1 · derivative.exercise_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. F1 · derivative.expiration_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| June 30, 2008 Filed Jul 17, 2008 21:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 1,107.53 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-08-012137 · doc4.xml · derivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,300.71 Underlying: Common Stock, $0.10 par value · 1,107.53 shares Expires not disclosed F1 · derivative.exercise_price: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. F1 · derivative.exercise_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. F1 · derivative.expiration_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 31, 2008 Filed Apr 2, 2008 20:41 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantDeferred Share Units · Derivative | 58.52 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000014272-08-000129 · sat853.xml · derivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,068.73 Underlying: Common Stock, $0.10 par value · 58.52 shares Expires not disclosed F1 · derivative.exercise_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. F1 · derivative.expiration_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| February 01, 2008 Filed Feb 5, 2008 21:27 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantDeferred Share Units · Derivative | 4,648 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000014272-08-000046 · sat794.xml · derivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,010.21 Underlying: Common Stock, $0.10 par value · 4,648 shares Expires not disclosed F1 · derivative.exercise_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. F1 · derivative.expiration_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 31, 2007 Filed Jan 3, 2008 22:08 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantDeferred Share Units · Derivative | 127.88 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000014272-08-000012 · sat772.xml · derivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,305.81 Underlying: Common Stock, $0.10 par value · 127.88 shares Expires not disclosed F1 · derivative.exercise_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. F1 · derivative.expiration_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. Read SEC document |
| September 28, 2007 Filed Oct 2, 2007 21:05 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantDeferred Share Units · Derivative | 118.78 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000014272-07-000200 · sat760.xml · derivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,138.9 Underlying: Common Stock, $0.10 par value · 118.78 shares Expires not disclosed F1 · derivative.exercise_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. F1 · derivative.expiration_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| June 29, 2007 Filed Jul 3, 2007 20:05 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantDeferred Share Units · Derivative | 108.85 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000014272-07-000164 · sat743.xml · derivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,980.87 Underlying: Common Stock, $0.10 par value · 108.85 shares Expires not disclosed F1 · derivative.exercise_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. F1 · derivative.expiration_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 30, 2007 Filed Apr 3, 2007 19:47 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantDeferred Share Units · Derivative | 123.83 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000014272-07-000101 · sat695.xml · derivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,835.08 Underlying: Common Stock, $0.10 par value · 123.83 shares Expires not disclosed F1 · derivative.exercise_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. F1 · derivative.expiration_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| February 01, 2007 Filed Feb 5, 2007 21:45 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantDeferred Share Units · Derivative | 3,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000014272-07-000044 · sat657.xml · derivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,711.25 Underlying: Common Stock, $0.10 par value · 3,500 shares Expires not disclosed F1 · derivative.exercise_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. F1 · derivative.expiration_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 29, 2006 Filed Jan 3, 2007 20:19 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantDeferred Share Units · Derivative | 107.06 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000014272-07-000013 · sat639.xml · derivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209.23 Underlying: Common Stock, $0.10 par value · 107.06 shares Expires not disclosed F1 · derivative.exercise_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. F1 · derivative.expiration_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| September 29, 2006 Filed Oct 3, 2006 21:06 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantDeferred Share Units · Derivative | 101.03 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000014272-06-000210 · sat618.xml · derivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101.03 Underlying: Common Stock, $0.10 par value · 101.03 shares Expires not disclosed F1 · derivative.exercise_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. F1 · derivative.expiration_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. Read SEC document |
| May 11, 2005 Filed May 12, 2005 20:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 7,000 | $0.00 Strike: $9.50 | $0.00 |
DisclosureSEC source: 0000875320-05-000019 · edgar.xml · derivative · entry 6 SATO VICKI L · CIK 0001197020 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 910,655 Underlying: Common Stock · 7,000 shares Expires 2005-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Right to buy under 1994 Stock and Option Plan, vesting quarterly over 5 years from 12/14/1995. F4 · balance_after: Reflects option to purchase 61,164 shares of common stock cancelled by the Company pursuant to a Severance Agreement and Release dated February 7, 2005. Read SEC document |
| May 11, 2005 Filed May 12, 2005 20:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Disposition to issuerCommon Stock | 28,875 | $0.01 | $288.75 |
DisclosureSEC source: 0000875320-05-000019 · edgar.xml · nonDerivative · entry 4 SATO VICKI L · CIK 0001197020 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,233 F2 · kind: Restricted Shares repurchased by the Company pursuant to a Severance Agreement and Release dated February 7, 2005. Read SEC document |
| May 11, 2005 Filed May 12, 2005 20:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Disposition to issuerCommon Stock | 2,000 | $0.01 | $20.00 |
DisclosureSEC source: 0000875320-05-000019 · edgar.xml · nonDerivative · entry 3 SATO VICKI L · CIK 0001197020 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,108 F2 · kind: Restricted Shares repurchased by the Company pursuant to a Severance Agreement and Release dated February 7, 2005. Read SEC document |
| May 11, 2005 Filed May 12, 2005 20:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 7,000 | $13.17 | $92,190.00 |
DisclosureSEC source: 0000875320-05-000019 · edgar.xml · nonDerivative · entry 2 SATO VICKI L · CIK 0001197020 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,108 F1 · kind: Transaction made pursuant to Dr. Sato's company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 11, 2005 Filed May 12, 2005 20:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 7,000 | $9.50 | $66,500.00 |
DisclosureSEC source: 0000875320-05-000019 · edgar.xml · nonDerivative · entry 1 SATO VICKI L · CIK 0001197020 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,108 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2005 Filed Mar 3, 2005 18:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 7,000 | $0.00 Strike: $9.50 | $0.00 |
DisclosureSEC source: 0000875320-05-000018 · edgar.xml · derivative · entry 4 SATO VICKI L · CIK 0001197020 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 978,819 Underlying: Common Stock · 7,000 shares Expires 2005-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Right to buy under 1994 Stock and Option Plan, vesting quarterly over 5 years from 12/14/1995. Read SEC document |
| March 02, 2005 Filed Mar 3, 2005 18:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 7,000 | $11.52 | $80,640.00 |
DisclosureSEC source: 0000875320-05-000018 · edgar.xml · nonDerivative · entry 2 SATO VICKI L · CIK 0001197020 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,108 F1 · kind: Transaction made pursuant to Dr. Sato's company approved trading plan established under Rule 10b5-1. Read SEC document |
| March 02, 2005 Filed Mar 3, 2005 18:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 7,000 | $9.50 | $66,500.00 |
DisclosureSEC source: 0000875320-05-000018 · edgar.xml · nonDerivative · entry 1 SATO VICKI L · CIK 0001197020 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,108 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2005 Filed Feb 25, 2005 15:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 7,000 | $0.00 Strike: $9.50 | $0.00 |
DisclosureSEC source: 0000875320-05-000017 · edgar.xml · derivative · entry 4 SATO VICKI L · CIK 0001197020 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 985,819 Underlying: Common Stock · 7,000 shares Expires 2005-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Right to buy under 1994 Stock and Option Plan, vesting quarterly over 5 years from 12/14/1995. Read SEC document |
| February 23, 2005 Filed Feb 25, 2005 15:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 7,000 | $11.05 | $77,350.00 |
DisclosureSEC source: 0000875320-05-000017 · edgar.xml · nonDerivative · entry 2 SATO VICKI L · CIK 0001197020 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,108 F1 · kind: Transaction made pursuant to Dr. Sato's company approved trading plan established under Rule 10b5-1. Read SEC document |
| February 23, 2005 Filed Feb 25, 2005 15:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 7,000 | $9.50 | $66,500.00 |
DisclosureSEC source: 0000875320-05-000017 · edgar.xml · nonDerivative · entry 1 SATO VICKI L · CIK 0001197020 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,108 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2005 Filed Feb 17, 2005 16:31 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 7,000 | $0.00 Strike: $9.50 | $0.00 |
DisclosureSEC source: 0000875320-05-000015 · edgar.xml · derivative · entry 4 SATO VICKI L · CIK 0001197020 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 992,819 Underlying: Common Stock · 7,000 shares Expires 2005-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Right to buy under 1994 Stock and Option Plan, vesting quarterly over 5 years from 12/14/1995. Read SEC document |
| February 16, 2005 Filed Feb 17, 2005 16:31 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 7,000 | $11.33 | $79,310.00 |
DisclosureSEC source: 0000875320-05-000015 · edgar.xml · nonDerivative · entry 2 SATO VICKI L · CIK 0001197020 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,108 F1 · kind: Transaction made pursuant to Dr. Sato's company approved trading plan established under Rule 10b5-1. Read SEC document |
| February 16, 2005 Filed Feb 17, 2005 16:31 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 7,000 | $9.50 | $66,500.00 |
DisclosureSEC source: 0000875320-05-000015 · edgar.xml · nonDerivative · entry 1 SATO VICKI L · CIK 0001197020 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,108 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2005 Filed Feb 10, 2005 15:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 7,000 | $0.00 Strike: $9.50 | $0.00 |
DisclosureSEC source: 0000875320-05-000014 · edgar.xml · derivative · entry 4 SATO VICKI L · CIK 0001197020 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 999,819 Underlying: Common Stock · 7,000 shares Expires 2005-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Right to buy under 1994 Stock and Option Plan, vesting quarterly over 5 years from 12/14/1995. Read SEC document |
| February 09, 2005 Filed Feb 10, 2005 15:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 7,000 | $10.80 | $75,600.00 |
DisclosureSEC source: 0000875320-05-000014 · edgar.xml · nonDerivative · entry 2 SATO VICKI L · CIK 0001197020 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,108 F1 · kind: Transaction made pursuant to Dr. Sato's company approved trading plan established under Rule 10b5-1. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.